Ivor Royston

Ivor Royston

Birth date	March 22, 1945
Birth place	Boston, Massachusetts, United States
Nationality	American
Known for	Co-founding Hybritech, pioneering work in monoclonal antibodies

Ivor Royston (born March 22, 1945) is an American oncologist and entrepreneur known for his pioneering work in the development of monoclonal antibodies and his role in founding biotechnology companies. He is a prominent figure in the field of cancer research and has significantly contributed to the advancement of biotechnology in medicine.

Early Life and Education

Ivor Royston was born in Boston, Massachusetts. He pursued his undergraduate studies at Johns Hopkins University, where he earned a Bachelor of Arts degree in 1967. He then attended Stanford University School of Medicine, receiving his M.D. in 1972. During his time at Stanford, Royston developed an interest in immunology and oncology, which would shape his future career.

Career

Academic Career

After completing his medical degree, Royston joined the faculty at the University of California, San Diego (UCSD) in 1977. At UCSD, he focused on research in cancer immunology and the development of monoclonal antibodies for cancer treatment. His work laid the foundation for the use of monoclonal antibodies in therapeutics.

Biotechnology Ventures

In 1978, Royston co-founded Hybritech, one of the first biotechnology companies to focus on the development of monoclonal antibody technology. Hybritech's success in developing diagnostic and therapeutic products demonstrated the potential of biotechnology in medicine. The company was later acquired by Eli Lilly and Company in 1986.

Following the success of Hybritech, Royston continued to be involved in the biotechnology industry. He co-founded Forward Ventures, a venture capital firm that invests in early-stage life science companies. Through Forward Ventures, Royston has supported numerous startups in the biotechnology sector.

Contributions to Medicine

Royston's work in developing monoclonal antibodies has had a profound impact on the treatment of various diseases, particularly cancer. Monoclonal antibodies are now a standard component of many cancer therapies, providing targeted treatment options that improve patient outcomes.

Awards and Recognition

Ivor Royston has received numerous awards for his contributions to science and medicine. His work has been recognized by various professional organizations, and he continues to be an influential figure in the field of biotechnology.

Personal Life

Royston is married and has children. He remains active in the scientific community and continues to advocate for the advancement of biotechnology in medicine.

Also see

• Monoclonal antibody therapy
• Biotechnology
• Cancer immunotherapy
• Hybritech
• University of California, San Diego